Nicole Negar Davarpanah - 01 May 2025 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
Chief Medical Officer
Signature
/s/ Shane Ward, Attorney-in-Fact
Issuer symbol
CDTX
Transactions as of
01 May 2025
Net transactions value
$0
Form type
4
Filing time
12 May 2025, 20:40:21 UTC
Next filing
15 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davarpanah Nicole Negar Chief Medical Officer 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO /s/ Shane Ward, Attorney-in-Fact 12 May 2025 0002067554

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDTX Common Stock Award $0 +10,000 +46% $0.000000 31,692 01 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDTX Employee Stock Option (right to buy) Award $0 +20,000 $0.000000 20,000 01 May 2025 Common Stock 20,000 $21.75 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents time-based Restricted Stock Units (RSUs) granted on May 1, 2025. All RSUs vest in three equal annual installments, with 1/3 vesting on each of June 10, 2026, 2027, and 2028, subject to continuous service through each such Vesting Date.
F2 The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of May 1, 2025, subject to continuous service through each such Vesting Date.